Transaction DateRecipientSharesTypePriceValue
22nd February 2021David M. Wehner5,916Open or private sale$257.95$1,526,032.20
19th February 2021Louis J Jr Lavigne6,219Exercise of derivative$0.00
17th February 2021David M. Wehner1,356Open or private sale$270.38$366,635.28
15th February 2021David M. Wehner7,434Exercise of derivative$0.00
15th February 2021David M. Wehner5,998Exercise of derivative$0.00
15th February 2021David M. Wehner14,177Payment by withholding$270.50$3,834,878.50
15th February 2021David M. Wehner2,463Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.00
15th February 2021David M. Wehner526Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.00
15th February 2021David M. Wehner9,427Exercise of derivative$0.00
15th February 2021David M. Wehner675Exercise of derivative$0.00
Alector
Alector logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Alector, Inc. develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in 2013.


Ticker: ALEC
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1653087
Employees:
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals